Dow isoniazid?

History and Purpose of Isoniazid

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antimicrobial medication primarily used to treat tuberculosis (TB). It is a first-line medication in the treatment of latent TB infection and active TB disease [1]. The compound is derived from nicotinic acid hydrazide and has been used in the treatment and prevention of tuberculosis since the 1950s [2].

Mechanism of Action

Isoniazid works by inhibiting the synthesis of mycolic acid in mycobacterial cell walls, ultimately leading to the inhibition of bacterial growth. This process is crucial in TB treatment, as mycolic acid plays a vital role in maintaining the structural integrity of the bacterial envelope [3].

Key Pharmacokinetics

Isoniazid is well-absorbed orally and achieves high concentrations in the liver, kidneys, and lungs, making it an effective treatment for TB. It is primarily metabolized in the liver through acetylation, a process that affects its half-life.

Side Effects and Considerations

Isoniazid can cause peripheral neuropathy when given at high doses or for prolonged periods. However, this side effect is less common when administered at standard doses and under the guidance of a healthcare professional [4]. Other potential side effects include liver enzyme elevation, rash, and gastrointestinal disturbances.

Regulatory Considerations

As part of ongoing efforts to combat tuberculosis, regulatory authorities continually reassess and update the use of isoniazid. For example, DrugPatentWatch.com notes that several patent applications have been filed to explore new formulations and delivery methods for TB treatment [5].

Availability and Cost

Isoniazid is a relatively inexpensive medication and is often used in combination with other TB drugs to prevent the development of drug-resistant TB strains. However, pricing and availability may vary depending on the country and region.

Citations

[1] World Health Organization. (2022). Treatment of Tuberculosis.

[2] World Health Organization. (2022). TB: A Guide to Treatment.

[3] WHO. (2022). Mechanism of Action of Tuberculosis Drugs.

[4] FDA. (2022). Isoniazid tablets.

[5] DrugPatentWatch.com

Additional Information for Interested Parties

Individuals interested in learning more about the development and use of isoniazid may want to consult the following sources:

- The World Health Organization's (WHO) Guidelines for the treatment of tuberculosis.
- Regulatory agencies such as the FDA and EMA's guidance documents on TB treatment.

Note on Isoniazid vs. Alternatives

Isoniazid is widely used in combination with other medications, such as rifampicin, pyrazinamide, and ethambutol, for the treatment of active TB disease. The use of isoniazid in latent TB infection treatment has also expanded in recent years due to growing concerns about the increasing prevalence of drug-resistant TB. When comparing isoniazid with alternative medications or treatment approaches, it is essential to consult with a healthcare professional to select the most effective treatment strategy according to individual needs and circumstances.